Rejko KrÃœger

List of Publications by Year
in descending order

174	22,875	41344	8630
papers	citations	49 h-index	146 g-index

196	196	196	34220
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	AlaSOPro mutation in the gene encoding Î±-synuclein in Parkinson's disease. Nature Genetics, 1998, 18, 106-108.	21.4	3,711
3	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
4	Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature Genetics, 2009, 41, 1308-1312.	21.4	1,745
5	Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinsonâ€™s disease. Science, 2017, 357, 1255-1261.	12.6	600
6	Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Human Molecular Genetics, 2005, 14, 2099-2111.	2.9	514
7	Collaborative Analysis of Î±-Synuclein Gene Promoter Variability and Parkinson Disease. JAMA - Journal of the American Medical Association, 2006, 296, 661.	7.4	467
8	Loss-of-Function of Human PINK1 Results in Mitochondrial Pathology and Can Be Rescued by Parkin. Journal of Neuroscience, 2007, 27, 12413-12418.	3.6	466
9	Genetic Correction of a LRRK2 Mutation in Human iPSCs Links Parkinsonian Neurodegeneration to ERK-Dependent Changes in Gene Expression. Cell Stem Cell, 2013, 12, 354-367.	11.1	448
10	Reduced Basal Autophagy and Impaired Mitochondrial Dynamics Due to Loss of Parkinson's Disease-Associated Protein DJ-1. PLoS ONE, 2010, 5, e9367.	2.5	319
11	Increased susceptibility to sporadic Parkinson's disease by a certain combined ?-synuclein/apolipoprotein E genotype. Annals of Neurology, 1999, 45, 611-617.	5.3	273
12	UCHL1 is a Parkinson's disease susceptibility gene. Annals of Neurology, 2004, 55, 512-521.	5.3	227
13	The hallmarks of <scp>P</scp>arkinson's disease. FEBS Journal, 2013, 280, 5981-5993.	4.7	214
14	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
15	Nigral stimulation for resistant axial motor impairment in Parkinsonâ€™s disease? A randomized controlled trial. Brain, 2013, 136, 2098-2108.	7.6	186
16	Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism and Related Disorders, 2017, 45, 13-20.	2.2	149
17	Mitochondrial Protein Quality Control by the Proteasome Involves Ubiquitination and the Protease Omi. Journal of Biological Chemistry, 2008, 283, 12681-12685.	3.4	145
18	Mutation analysis and association studies of the UCHL1 gene in German ParkinsonÊ¼s disease patients. NeuroReport, 2000, 11, 2079-2082.	1.2	143

#	Article	IF	Citations
19	The genetic architecture of mitochondrial dysfunction in Parkinsonâ€™s disease. Cell and Tissue Research, 2018, 373, 21-37.	2.9	131
20	Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Human Molecular Genetics, 2003, 12, 1223-1231.	2.9	124
21	Parkinsonâ€™s disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions. BMC Biology, 2020, 18, 62.	3.8	122
22	Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: functional impact of disease-related variants on mitochondrial homeostasis. Human Molecular Genetics, 2010, 19, 4437-4452.	2.9	121
23	Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology, 2012, 79, 659-667.	1.1	119
24	Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). Human Mutation, 2004, 24, 321-329.	2.5	117
25	Effects of transcranial direct current stimulation (tDCS) on executive functions: Influence of COMT Val/Met polymorphism. Cortex, 2013, 49, 1801-1807.	2.4	117
26	Short- and long-term outcome of chronic pallidal neurostimulation in monogenic isolated dystonia. Neurology, 2015, 84, 895-903.	1.1	117
27	NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiology of Aging, 2017, 57, 247.e9-247.e13.	3.1	108
28	Review: Familial Parkinson's disease â€“ genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neuropathology and Applied Neurobiology, 2008, 34, 255-271.	3.2	105
29	Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurology, The, 2018, 17, 223-231.	10.2	105
30	Integrated Analyses of Microbiome and Longitudinal Metabolome Data Reveal Microbial-Host Interactions on Sulfur Metabolism in Parkinsonâ€™s Disease. Cell Reports, 2019, 29, 1767-1777.e8.	6.4	102
31	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. Journal of Medical Genetics, 2012, 49, 721-726.	3.2	94
32	Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Annals of Neurology, 2011, 69, 778-792.	5.3	92
33	First appraisal of brain pathology owing to A30P mutant alphaâ€synuclein. Annals of Neurology, 2010, 67, 684-689.	5.3	91
34	Î±-Synuclein in Parkinsonâ€™s disease: causal or bystander?. Journal of Neural Transmission, 2019, 126, 815-840.	2.8	88
35	Evaluating the Use of Circulating MicroRNA Profiles for Lung Cancer Detection in Symptomatic Patients. JAMA Oncology, 2020, 6, 714.	7.1	84
36	Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. Lancet Neurology, The, 2006, 5, 917-923.	10.2	83

#	Article	IF	Citations
37	Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinsonâ€™s disease. Brain, 2017, 140, 2444-2459.	7.6	76
38	The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides. Nature Communications, 2020, 11, 3033.	12.8	74
39	The COMT Val/Met Polymorphism Modulates Effects of tDCS on Response Inhibition. Brain Stimulation, 2015, 8, 283-288.	1.6	73
40	Parkinson's disease: one biochemical pathway to fit all genes?. Trends in Molecular Medicine, 2002, 8, 236-240.	6.7	68
41	Lateralisation in Parkinson disease. Cell and Tissue Research, 2018, 373, 297-312.	2.9	67
42	The modulation of Amyotrophic Lateral Sclerosis risk by Ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiology of Disease, 2012, 45, 356-361.	4.4	66
43	Subthalamic stimulation modulates cortical motor network activity and synchronization in Parkinsonâ€™s disease. Brain, 2015, 138, 679-693.	7.6	66
44	Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease. Journal of Neurology, 2007, 254, 613-616.	3.6	65
45	Classification of advanced stages of Parkinsonâ€™s disease: translation into stratified treatments. Journal of Neural Transmission, 2017, 124, 1015-1027.	2.8	64
46	The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p. Scientific Reports, 2017, 7, 12702.	3.3	62
47	Modulation of mitochondrial function and morphology by interaction of Omi/HtrA2 with the mitochondrial fusion factor OPA1. Experimental Cell Research, 2010, 316, 1213-1224.	2.6	57
48	The Luxembourg Parkinsonâ€™s Study: A Comprehensive Approach for Stratification and Early Diagnosis. Frontiers in Aging Neuroscience, 2018, 10, 326.	3.4	57
49	A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. Neurobiology of Aging, 2011, 32, 548.e9-548.e18.	3.1	56
50	Mutations in RHOT1 Disrupt Endoplasmic Reticulumâ€“Mitochondria Contact Sites Interfering with Calcium Homeostasis and Mitochondrial Dynamics in Parkinson's Disease. Antioxidants and Redox Signaling, 2019, 31, 1213-1234.	5.4	56
51	14-3-3 protein is a component of Lewy bodies in Parkinsonâ€™s diseaseâ€”Mutation analysis and association studies of 14-3-3 eta. Molecular Brain Research, 2002, 108, 33-39.	2.3	53
52	Converging environmental and genetic pathways in the pathogenesis of Parkinson's disease. Journal of the Neurological Sciences, 2011, 306, 1-8.	0.6	52
53	Knockdown of Hsc70-5/mortalin Induces Loss of Synaptic Mitochondria in a Drosophila Parkinsonâ€™s Disease Model. PLoS ONE, 2013, 8, e83714.	2.5	51
54	The proteasomal subunit S6 ATPase is a novel synphilinâ€1 interacting proteinâ€”implications for Parkinson's disease. FASEB Journal, 2007, 21, 1759-1767.	0.5	48

#	Article	IF	Citations
55	Loss of DJ-1 impairs antioxidant response by altered glutamine and serine metabolism. Neurobiology of Disease, 2016, 89, 112-125.	4.4	47
56	Combined stimulation of the substantia nigra pars reticulata and the subthalamic nucleus is effective in hypokinetic gait disturbance in Parkinsonâ€™s disease. Journal of Neurology, 2011, 258, 1183-1185.	3.6	46
57	Management of Parkinsonâ€™s Disease 20 Years from Now: Towards Digital Health Pathways. Journal of Parkinson's Disease, 2018, 8, S85-S94.	2.8	46
58	Common diseases alter the physiological age-related blood microRNA profile. Nature Communications, 2020, 11, 5958.	12.8	46
59	Involvement of the cerebellum in Parkinson disease and dementia with Lewy bodies. Annals of Neurology, 2017, 81, 898-903.	5.3	44
60	Haploinsufficiency at the Â-synuclein gene underlies phenotypic severity in familial Parkinson's disease. Brain, 2003, 126, 32-42.	7.6	43
61	Machine learning-assisted neurotoxicity prediction in human midbrain organoids. Parkinsonism and Related Disorders, 2020, 75, 105-109.	2.2	41
62	Balance is the challenge â€“ The impact of mitochondrial dynamics in Parkinsonâ€™s disease. European Journal of Clinical Investigation, 2010, 40, 1048-1060.	3.4	40
63	Costâ€effectiveness of neurostimulation in Parkinson's disease with early motor complications. Movement Disorders, 2016, 31, 1183-1191.	3.9	39
64	Variants in Miro1 Cause Alterations of ER-Mitochondria Contact Sites in Fibroblasts from Parkinsonâ€™s Disease Patients. Journal of Clinical Medicine, 2019, 8, 2226.	2.4	39
65	Impaired mitochondrialâ€“endoplasmic reticulum interaction and mitophagy in Miro1-mutant neurons in Parkinsonâ€™s disease. Human Molecular Genetics, 2020, 29, 1353-1364.	2.9	37
66	Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by <scp>2â€Hydroxypropylâ€Î²â€Cyclodextrin</scp> Treatment. Movement Disorders, 2022, 37, 80-94.	3.9	37
67	The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. Neurobiology of Aging, 2014, 35, 266.e5-266.e14.	3.1	36
68	Advanced stages of PD: interventional therapies and related patient-centered care. Journal of Neural Transmission, 2016, 123, 31-43.	2.8	34
69	A novel heterozygousOPA3mutation located in the mitochondrial target sequence results in altered steady-state levels and fragmented mitochondrial network. Journal of Medical Genetics, 2013, 50, 848-858.	3.2	33
70	Prodromal Markers in Parkinsonâ€™s Disease: Limitations in Longitudinal Studies and Lessons Learned. Frontiers in Aging Neuroscience, 2016, 8, 147.	3.4	33
71	Mitochondrial Morphology, Function and Homeostasis Are Impaired by Expression of an N-terminal Calpain Cleavage Fragment of Ataxin-3. Frontiers in Molecular Neuroscience, 2018, 11, 368.	2.9	32
72	Mitochondrial and Clearance Impairment in p.<scp>D620N VPS35</scp> Patientâ€Derived Neurons. Movement Disorders, 2021, 36, 704-715.	3.9	32

#	Article	IF	Citations
73	The Role of DJ-1 in Cellular Metabolism and Pathophysiological Implications for Parkinsonâ€™s Disease. Cells, 2021, 10, 347.	4.1	31
74	Populationâ€specific frequencies for LRRK2 susceptibility variants in the genetic epidemiology of Parkinson's disease (GEOâ€PD) consortium. Movement Disorders, 2013, 28, 1740-1744.	3.9	30
75	The Emerging Role of RHOT1/Miro1 in the Pathogenesis of Parkinson's Disease. Frontiers in Neurology, 2020, 11, 587.	2.4	30
76	Effects of Subthalamic and Nigral Stimulation on Gait Kinematics in Parkinsonâ€™s Disease. Frontiers in Neurology, 2017, 8, 543.	2.4	29
77	Mutation analysis of the neurofilament M gene in Parkinson's disease. Neuroscience Letters, 2003, 351, 125-129.	2.1	28
78	Olfactory neuron-specific expression of A30P alpha-synuclein exacerbates dopamine deficiency and hyperactivity in a novel conditional model of early Parkinson's disease stages. Neurobiology of Disease, 2011, 44, 192-204.	4.4	28
79	Missing heritability in Parkinsonâ€™s disease: the emerging role of non-coding genetic variation. Journal of Neural Transmission, 2020, 127, 729-748.	2.8	27
80	Mitochondrial translation initiation factor 3 gene polymorphism associated with Parkinson's disease. Neuroscience Letters, 2007, 414, 126-129.	2.1	26
81	Long-term outcome of deep brain stimulation in fragile X-associated tremor/ataxia syndrome. Parkinsonism and Related Disorders, 2015, 21, 310-313.	2.2	26
82	Deep sequencing of sncRNAs reveals hallmarks and regulatory modules of the transcriptome during Parkinsonâ€™s disease progression. Nature Aging, 2021, 1, 309-322.	11.6	26
83	The NG2 Proteoglycan Protects Oligodendrocyte Precursor Cells against Oxidative Stress via Interaction with OMI/HtrA2. PLoS ONE, 2015, 10, e0137311.	2.5	26
84	Genetic dissection of familial Parkinson's disease. Trends in Molecular Medicine, 1998, 4, 438-444.	2.6	25
85	A comprehensive genetic study of the proteasomal subunit S6 ATPase in German Parkinsonâ€™s disease patients. Journal of Neural Transmission, 2008, 115, 1141-1148.	2.8	25
86	Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. Neurology, 2015, 85, 1283-1292.	1.1	25
87	Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease. Neurology, 2022, 99, .	1.1	25
88	Central oscillators in a patient with neuropathic tremor: Evidence from intraoperative local field potential recordings. Movement Disorders, 2011, 26, 323-327.	3.9	24
89	Long-term follow-up of subthalamic nucleus stimulation in glucocerebrosidase-associated Parkinsonâ€™s disease. Journal of Neurology, 2012, 259, 1970-1972.	3.6	24
90	An Observational Study of the Effect of Levodopaâ€“Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinsonâ€™s Disease Patients. Advances in Therapy, 2017, 34, 1741-1752.	2.9	24

#	Article	IF	Citations
91	A patient-based model of RNA mis-splicing uncovers treatment targets in Parkinsonâ€™s disease. Science Translational Medicine, 2020, 12, .	12.4	24
92	The role of synphilin-1 in synaptic function and protein degradation. Cell and Tissue Research, 2004, 318, 195-199.	2.9	23
93	Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease - Report of the JPND Working Group BioLoC-PD. Neuroepidemiology, 2015, 45, 282-297.	2.3	23
94	EIF4G1is neither a strong nor a common risk factor for Parkinson's disease: evidence from large European cohorts: Table1. Journal of Medical Genetics, 2015, 52, 37-41.	3.2	23
95	Genetic Architecture of Parkinson's Disease in the Indian Population: Harnessing Genetic Diversity to Address Critical Gaps in Parkinson's Disease Research. Frontiers in Neurology, 2020, 11, 524.	2.4	23
96	LRRK2in Parkinson's disease â€“ drawing the curtain of penetrance: a commentary. BMC Medicine, 2008, 6, 33.	5.5	22
97	Clinically meaningful parameters of progression and long-term outcome of Parkinson disease: An international consensus statement. Parkinsonism and Related Disorders, 2015, 21, 675-682.	2.2	22
98	Cortical correlates of susceptibility to upper limb freezing in Parkinsonâ€™s disease. Clinical Neurophysiology, 2016, 127, 2386-2393.	1.5	22
99	Neuromuscular correlates of subthalamic stimulation and upper limb freezing in Parkinsonâ€™s disease. Clinical Neurophysiology, 2016, 127, 610-620.	1.5	21
100	PINK1 deficiency impairs adult neurogenesis of dopaminergic neurons. Scientific Reports, 2021, 11, 6617.	3.3	21
101	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 267-282.	2.8	21
102	Acute parkinsonism with corresponding lesions in the basal ganglia after heroin abuse. Neurology, 2007, 68, 414-414.	1.1	20
103	Overexpression of synphilin-1 promotes clearance of soluble and misfolded alpha-synuclein without restoring the motor phenotype in aged A30P transgenic mice. Human Molecular Genetics, 2014, 23, 767-781.	2.9	20
104	Mutation analyses and association studies to assess the role of the presenilin-associated rhomboid-like gene in Parkinson's disease. Neurobiology of Aging, 2016, 39, 217.e13-217.e15.	3.1	20
105	Human Dopaminergic Neurons Lacking PINK1 Exhibit Disrupted Dopamine Metabolism Related to Vitamin B6 Co-Factors. IScience, 2020, 23, 101797.	4.1	20
106	Integrated, automated maintenance, expansion and differentiation of 2D and 3D patient-derived cellular models for high throughput drug screening. Scientific Reports, 2021, 11, 1439.	3.3	20
107	The Parkinsonâ€™s-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1. Cell Reports, 2021, 37, 109864.	6.4	20
108	Mitochondrial defects and neurodegeneration in mice overexpressing wild-type or G399S mutant HtrA2. Human Molecular Genetics, 2016, 25, 459-471.	2.9	19

#	Article	IF	Citations
109	Transgenic overexpression of the alpha-synuclein interacting protein synphilin-1 leads to behavioral and neuropathological alterations in mice. Neurogenetics, 2010, 11, 107-120.	1.4	18
110	Combined STN/SNr-DBS for the treatment of refractory gait disturbances in Parkinson's disease: study protocol for a randomized controlled trial. Trials, 2011, 12, 222.	1.6	18
111	The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease. Journal of Visualized Experiments, 2012, , .	0.3	18
112	PARK7/DJ-1 promotes pyruvate dehydrogenase activity and maintains Treg homeostasis during ageing. Nature Metabolism, 2022, 4, 589-607.	11.9	18
113	From Genome-Wide Association Studies to Next-Generation Sequencing. JAMA Neurology, 2014, 71, 5.	9.0	17
114	Using High-Content Screening to Generate Single-Cell Gene-Corrected Patient-Derived iPS Clones Reveals Excess Alpha-Synuclein with Familial Parkinsonâ€™s Disease Point Mutation A30P. Cells, 2020, 9, 2065.	4.1	17
115	Genetic analysis of the Î±2-macroglobulin gene in early-and late-onset ParkinsonÊ¼s disease. NeuroReport, 2000, 11, 2439-2442.	1.2	16
116	Evaluation of the Î³-synuclein gene in German Parkinson's disease patients. Neuroscience Letters, 2001, 310, 191-193.	2.1	16
117	Subthalamic nucleus stimulation restores the efferent cortical drive to muscle in parallel to functional motor improvement. European Journal of Neuroscience, 2012, 35, 896-908.	2.6	16
118	Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials. Parkinsonism and Related Disorders, 2015, 21, 742-748.	2.2	16
119	Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies. Frontiers in Aging Neuroscience, 2016, 8, 121.	3.4	16
120	<scp>A</scp>lphaâ€synuclein gene variants may predict neurostimulation outcome. Movement Disorders, 2016, 31, 601-603.	3.9	15
121	Bidirectional Relation Between Parkinson's Disease and Glioblastoma Multiforme. Frontiers in Neurology, 2020, 11, 898.	2.4	15
122	Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study. Movement Disorders, 2022, 37, 857-864.	3.9	15
123	Alphaâ€synuclein repeat variants and survival in Parkinson's disease. Movement Disorders, 2014, 29, 1053-1057.	3.9	14
124	Understanding the role of genetic variability in LRRK2 in Indian population. Movement Disorders, 2019, 34, 496-505.	3.9	14
125	Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase. Npj Parkinson's Disease, 2021, 7, 29.	5.3	14
126	Connecting environmental exposure and neurodegeneration using cheminformatics and high resolution mass spectrometry: potential and challenges. Environmental Sciences: Processes and Impacts, 2019, 21, 1426-1445.	3.5	13

#	Article	IF	Citations
127	Automated high-throughput high-content autophagy and mitophagy analysis platform. Scientific Reports, 2019, 9, 9455.	3.3	13
128	Anodal tDCS modulates cortical activity and synchronization in Parkinson's disease depending on motor processing. NeuroImage: Clinical, 2019, 22, 101689.	2.7	13
129	Unraveling Molecular Mechanisms of THAP1 Missense Mutations in DYT6 Dystonia. Journal of Molecular Neuroscience, 2020, 70, 999-1008.	2.3	13
130	Haploinsufficiency due to a novel ACO2 deletion causes mitochondrial dysfunction in fibroblasts from a patient with dominant optic nerve atrophy. Scientific Reports, 2020, 10, 16736.	3.3	12
131	Unmet Needs of People With Parkinson's Disease and Their Caregivers During COVID-19-Related Confinement: An Explorative Secondary Data Analysis. Frontiers in Neurology, 2020, 11, 615172.	2.4	12
132	GDAP1 loss of function inhibits the mitochondrial pyruvate dehydrogenase complex by altering the actin cytoskeleton. Communications Biology, 2022, 5, .	4.4	12
133	The evolution and social determinants of mental health during the first wave of the COVID-19 outbreak in Luxembourg. Psychiatry Research, 2021, 303, 114090.	3.3	11
134	PCR/SSCP Detects Reliably and Efficiently DNA Sequence Variations in Large Scale Screening Projects. Combinatorial Chemistry and High Throughput Screening, 2000, 3, 211-218.	1.1	11
135	PINK1 Protects against Staurosporine-Induced Apoptosis by Interacting with Beclin1 and Impairing Its Pro-Apoptotic Cleavage. Cells, 2022, 11, 678.	4.1	11
136	Spectrum of phenotypes and genotypes in Parkinson's disease. Journal of Neurology, 2002, 249, 1-1.	3.6	10
137	Excess of singleton loss-of-function variants in Parkinsonâ€™s disease contributes to genetic risk. Journal of Medical Genetics, 2020, 57, 617-623.	3.2	10
138	Genes in familial parkinsonism and their role in sporadic Parkinson?s disease. Journal of Neurology, 2004, 251, VI/2-6.	3.6	9
139	Gene-environment interaction and Mendelian randomisation. Revue Neurologique, 2019, 175, 597-603.	1.5	9
140	DJâ€‰1 depletion prevents immunoaging in Tâ€‰cell compartments. EMBO Reports, 2022, 23, e53302.	4.5	9
141	Family-based association study on functional Î±-synuclein polymorphisms in attention-deficit/hyperactivity disorder. ADHD Attention Deficit and Hyperactivity Disorders, 2019, 11, 107-111.	1.7	8
142	Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study. Neurobiology of Aging, 2017, 49, 217.e1-217.e4.	3.1	7
143	Mitochondria interaction networks show altered topological patterns in Parkinsonâ€™s disease. Npj Systems Biology and Applications, 2020, 6, 38.	3.0	7
144	Impact of COVID-19 Pandemic on (Health) Care Situation of People with Parkinsonâ€™s Disease in Germany (Care4PD). Brain Sciences, 2022, 12, 62.	2.3	7

#	Article	IF	Citations
145	The Moderating Role of Resilience in the Personality-Mental Health Relationship During the COVID-19 Pandemic. Frontiers in Psychiatry, 2021, 12, 745636.	2.6	6
146	Large-scale validation of miRNAs by disease association, evolutionary conservation and pathway activity. RNA Biology, 2019, 16, 93-103.	3.1	5
147	Quality Control Strategy for CRISPR-Cas9-Based Gene Editing Complicated by a Pseudogene. Frontiers in Genetics, 2019, 10, 1297.	2.3	5
148	Generation of two iPS cell lines (HIHDNDi001-A and HIHDNDi001-B) from a Parkinsonâ€™s disease patient carrying the heterozygous p.A30P mutation in SNCA. Stem Cell Research, 2020, 48, 101951.	0.7	5
149	Induced pluripotent stem cell line (LCSBi001-A) derived from a patient with Parkinson's disease carrying the p.D620N mutation in VPS35. Stem Cell Research, 2020, 45, 101776.	0.7	5
150	Editorial: Celebrating the Diversity of Genetic Research to Dissect the Pathogenesis of Parkinson's Disease. Frontiers in Neurology, 2021, 12, 648417.	2.4	5
151	Exploring the contribution of the mitochondrial disulfide relay system to Parkinsonâ€™s disease: the PINK1/CHCHD4 interplay. Neural Regeneration Research, 2021, 16, 2222.	3.0	5
152	Therapeutic strategies for Parkinson's disease based on data derived from genetic research. Journal of Neurology, 2003, 250, i3-i10.	3.6	4
153	The Interaction between <scp>HLAâ€ĐRB1</scp> and Smoking in Parkinson's Disease Revisited. Movement Disorders, 2022, 37, 1929-1937.	3.9	4
154	Long-Term Effect of GPi-DBS in a Patient With Generalized Dystonia Due to GLUT1 Deficiency Syndrome. Frontiers in Neurology, 2018, 9, 381.	2.4	3
155	Multilingual Validation of the First French Version of Munich Dysphagia Testâ€"Parkinson's Disease (MDT-PD) in the Luxembourg Parkinson's Study. Frontiers in Neurology, 2019, 10, 1180.	2.4	3
156	Smart Scheduling (SMASCH): multi-appointment scheduling system for longitudinal clinical research studies. JAMIA Open, 2022, 5, .	2.0	3
157	Periphilin is a novel interactor of synphilin-1, a protein implicated in Parkinson's disease. Neurogenetics, 2010, 11, 203-215.	1.4	2
158	The subthalamic nucleus modulates the early phase of probabilistic classification learning. Experimental Brain Research, 2014, 232, 2255-2262.	1.5	2
159	Reply: No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinsonâ€™s disease. Brain, 2018, 141, e17-e17.	7.6	2
160	Quantifying activities of daily living impairment in Parkinsonâ€™s disease using the Functional Activities Questionnaire. Neurological Sciences, 2022, 43, 1047-1054.	1.9	2
161	Gene-corrected p.A30P SNCA patient-derived isogenic neurons rescue neuronal branching and function. Scientific Reports, 2021, 11, 21946.	3.3	2
162	Additive Effect of Dopaminergic Medication on Gait Under Single and Dual-Tasking Is Greater Than of Deep Brain Stimulation in Advanced Parkinson Disease With Long-duration Deep Brain Stimulation. Neuromodulation, 2022, , .	0.8	2

#	Article	IF	Citations
163	Generation and characterization of a genetic Parkinsonâ€™s disease-patient derived iPSC line DJ-1-delP (LCSBi008-A). Stem Cell Research, 2022, 62, 102792.	0.7	2
164	Further delineation of the association signal on chromosome 5 from the first whole genome association study in Parkinson's disease. Neurobiology of Aging, 2009, 30, 1706-1709.	3.1	1
165	Contributing Factors and Evolution of Impulse Control Disorder in the Luxembourg Parkinson Cohort. Frontiers in Neurology, 2020, 11, 578924.	2.4	1
166	Loss of Mortalin Function in Parkinsonâ€™s Disease-Supporting the Mitochondrial Pathway of Neurodegeneration. , 2012, , 159-177.		0
167	Comment onâ€œ Classification of Advanced Stages of Parkinsonâ€™s Disease: Translation into Stratified Treatmentsâ€• International Journal of Neurorehabilitation, 2017, 04, .	0.1	0
168	Adverse Life Trajectories Are a Risk Factor for SARS-CoV-2 IgA Seropositivity. Journal of Clinical Medicine, 2021, 10, 2159.	2.4	0
169	PARK3, Ubiquitin Hydrolase-L1 and Other PD Loci. , 2003, , 315-323.		0
170	Therapeutic maps for a sensor-based evaluation of deep brain stimulation programming. Biomedizinische Technik, 2021, 66, 603-611.	0.8	0
171	Analysis and visualisation of tremor dynamics in deep brain stimulation patients. Current Directions in Biomedical Engineering, 2020, 6, 115-118.	0.4	0
172	A rule-based expert system for real-time feedback-control in deep brain stimulation. Current Directions in Biomedical Engineering, 2020, 6, 103-106.	0.4	0
173	Prevalence and Cost of Care for Parkinsonâ€™s Disease in Luxembourg: An Analysis of National Healthcare Insurance Data. PharmacoEconomics - Open, 2022, , .	1.8	0
174	Generation of isogenic control DJ-1-delP GC13 for the genetic Parkinsonâ€˜s disease-patient derived iPSC line DJ-1-delP (LCSBi008-A-1). Stem Cell Research, 2022, 62, 102815.	0.7	0